Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 19/20 | 0.70 |
| ▸ | MMP13 | P45452 | 1/20 | 0.68 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.61 |
| ▸ | MMP3 | P08254 | 1/20 | 0.61 |
| ▸ | MMP7 | P09237 | 1/20 | 0.61 |
| ▸ | ADAMTS1 | Q9UHI8 | 1/20 | 0.61 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6595309 | 0.92 | ADAM17 (0.83) | ADAM17MMP13ADAMTS4MMP3MMP7 | |
| SCHEMBL6594102 | 0.85 | ADAM17 (0.87) | ADAM17MMP13ADAMTS4MMP3MMP7 | |
| SCHEMBL6595754 | 0.82 | ADAM17 (1.00) | ADAM17MMP13ADAMTS4MMP3MMP7 | |
| SCHEMBL6597438 | 0.81 | ADAM17 (1.00) | ADAM17MMP13ADAMTS4MMP3MMP7 | |
| SCHEMBL6595241 | 0.81 | ADAM17 (0.85) | ADAM17MMP13ADAMTS4MMP3MMP7 | |
| SCHEMBL6597738 | 0.81 | ADAM17 (1.00) | ADAM17MMP13ADAMTS4MMP3MMP7 | |
| SCHEMBL6599951 | 0.81 | ADAM17 (1.00) | ADAM17MMP13ADAMTS4MMP3MMP7 | |
| SCHEMBL6596595 | 0.81 | ADAM17 (1.00) | ADAM17MMP13ADAMTS4MMP3MMP7 | |
| SCHEMBL6595830 | 0.80 | ADAM17 (1.00) | ADAM17MMP13ADAMTS4MMP3MMP7 | |
| SCHEMBL6595527 | 0.80 | ADAM17 (0.87) | ADAM17MMP13ADAMTS4MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | TNF, XPNPEP1, MMP2 | ADAM17 27/4885MMP13 16/4885ADAMTS4 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.